Ohana Vaccines uses a proprietary prime-boost strategy to cause the destruction of established prostate cancer
IS THE NEW SOLUTION
With an estimated $19B total prostate cancer treatment cost by 2020, Ohana Vaccine targets the 20-30% of recurrent prostate cancer.
Ohana Vaccines is on track to complete clinical trials by the end of 2018 and is ready to scale rapidly to production.
A patent is already filed and there are no comparable competitive Immunotherapy treatments.
Prostate Cancer Treatment Opportunities
~ 30 %
Globally there are 1.11 M new cases and 307,000 deaths.
In 2018, 164,650 men in the US will be diagnosed with prostate cancer and greater than 26,000 will die.
After initial treatment, about
20-30% of men will show signs of cancer recurrence.